Office of the General CounselBApril  The Honorable James M Jeffords Chairman The Honorable Edward MKennedy Ranking Minority Member Committee on Health EducationLabor and Pensions United States SenateThe Honorable Thomas J Bliley Jr Chairman The Honorable JohnD Dingell Ranking Minority Member Committee on Commerce House ofRepresentativesSubject Department of Health and Human Services Food and DrugAdministration OvertheCounter Human Drugs LabelingRequirementsPursuant to section aA of title  United States Codethis is our report on a major rule promulgated by the Department ofHealth and Human Services Food and Drug Administration FDAentitled OvertheCounter Human Drugs Labeling RequirementsRIN AA We received the rule on March   It waspublished in the Federal Register as a final rule on March   Fed Reg The final rule establishes a standardized format andstandardized content requirements for the labeling ofoverthecounter drug productsThe final rule has an announced effective date of April  which is less than the day delay in a major ruleseffective date required by the Small Business RegulatoryEnforcement Fairness Act of   USC  a The FDAgives no reason in the rules preamble as to why the day delayprovision was not met While the rule has varying compliance datesthat are much later than the announced effective date of the rulesome previously approved products covered by the rule have severalyears to become compliant with the labeling requirement we donoteGAOOGCthat products which have drug marketing applications approved onor after April   must comply upon approvalEnclosed is our assessment of the FDAs compliance with theprocedural steps required by section aBi through ivof title  with respect to the rule Our review indicates that theFDA with the exception of the failure to allow the day delaycomplied with the applicable requirementsIf you have any questions about this report please contactJames W Vickers Assistant General Counsel at   Theofficial responsible for GAO evaluation work relating to theDepartment of Health and Human Services Food and DrugAdministration is William Scanlon Director Health Financing andPublic Health Issues Mr Scanlon can be reached at Robert P Murphy General CounselEnclosurecc Ms Jackie White Deputy Executive Secretariat Department ofHealth and Human ServicesPage  GAOOGCENCLOSUREANALYSIS UNDER  USC  aBiiv OF A MAJOR RULEISSUED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD ANDDRUG ADMINISTRATION ENTITLED OVERTHECOUNTER HUMAN DRUGSLABELING REQUIREMENTS RIN AAi Costbenefit analysisThe FDA performed a costbenefit analysis of the final rule Theanalysis estimates that the onetime costs of the rule to be about million with annual recurring costs of about  millionThe health benefits could not be quantified by the FDA but FDAbelieves the benefits to be substantial If the rule prevents percent of the hospitalizations associated with the unintendedconsequences of selfmedication the economic savings could be million annually in direct benefits and  million annually fromindirect benefits In addition the rule is expected to producemore efficient consumer search activities which could lead to timesavings valued at  million to  million per year Based on theabove the total benefits of the rule range from  million to million per yearii Agency actions relevant to the Regulatory Flexibility Act USC    and The preamble to the final rule contains the Final RegulatoryFlexibility Analysis conducted by the FDAUsing the Small Business Administrations size designation forthis industry of fewer than  employees FDA estimates that percent of the  firms in the industry would be considered smallentitiesFDA finds that the onetime cost of compliance for each productestimated to be  should be manageable for small entities evenif they manufacture  to  products that require relabeling at acost of  to The analysis also discusses the alternatives considered such asdifferent compliance dates and the reasons for the alternativeselectedGAOOGCiii Agency actions relevant to sections  of theUnfunded Mandates Reform Act of   USC  FDA has found that the final rule will not impose a mandate oneither state local or tribal governments or the private sector inany one year of  million or moreiv Other relevant information or requirements under acts andexecutive ordersAdministrative Procedure Act  USC   et seqThe final rule was issued using the notice and commentprocedures found at  USC  On February   the FDA published a Notice of ProposedRulemaking in the Federal Register  Fed Reg  The FDAreceived over  comments and discusses the comments and thechanges it made to the proposed rule in the preamble to the finalrulePaperwork Reduction Act  USC  The final rule contains information collections which aresubject to review by the Office of Management and Budget under thePaperwork Reduction ActThe preamble to the final rule contains the information requiredby the Act including a description of the collection the reasonfor the collection and an estimate of the annual burden hoursimposedFDA estimates that the total burden hours annually will be with  hours being a onetime burden The burden hoursare not higher because with the varied compliance dates for thelabeling many manufacturers will be able to change the labels aspart of the usual and customary business practice of redesigningthe labels and therefore no additional burden is incurredStatutory authorization for the ruleThe final rule was issued pursuant to the authority of theFederal Food Drug and Cosmetic Act and the Public Health ServiceAct as codified at  USC         b ggss   e and  USC    and Page  GAOOGCExecutive Order No The final rule was reviewed by the Office of Management andBudget and determined to be an economically significant regulatoryaction and approved as complying with the orderPage  GAOOGC